NCT04457830Unknown2 期
A Phase 2, Open-label, Single-arm, Multicenter Study of the Efficacy and Safety of F520 in Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 105
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase II clinical study to evaluate the efficacy and safety of F520 for the treatment of relapsed and refractory peripheral T cell lymphoma (PTCL), and to evaluate the immunogenicity of F520.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or older, male or female;
- •Histologically confirmed relapsed or refractory PTCL patients who had received systemic treatment at least once but had failed to; Relapsed / refractory is defined as follows:
- •Relapsed: patients who have new lesions at the primary site or other sites after reaching CR in the previous treatment; Refractory: patients who fail to reach PR in 2 cycles or CR in 4 cycles after first-line or above systemic treatment; if the best effect or end cause is PD, the number of cycles is not required;
- •ECOG score of 0-2;
- •Life expectancy≥3 months;
- •Agree to provide archived tumor tissue samples or fresh tissue samples, including enough samples to complete PD-L1 test;
- •Computed tomography (ct) scans should show the presence of at least one of two vertical orientations; The tumor lesions that could be measured were defined, with the longest diameter of intranode lesion > 1.5cm, the shortest diameter of intranode lesion > 1.0cm and the longest diameter of extranode lesion > 1.0cm;
- •The functions of important organs meet the following requirements (drugs with any blood component and cell growth factor are not allowed to be used within 14 days before the first administration):
- •routine blood tests: hemoglobin ≥ 90 g/L, neutrophil ≥ 1.5 ×109/L, platelet ≥ 75×109/L; Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); If there is liver metastasis, TBIL ≤ 3 × ULN, ALT and AST ≤ 5 × ULN; Serum creatinine ≤ 1.5×ULN; Thyroid function indicators: thyroid-stimulating hormone (TSH) are within the normal range or thyroid-stimulating hormone (TSH) are not within the normal range and free thyroxine (FT3/FT4) are within the normal range;
- •Sign the written informed consent, and be able to follow the visit and related procedures specified in the protocol.
排除标准
- •Diagnosed as vascular immunoblastic t-cell lymphoma (AITL) or adult t-cell lymphoma/leukemia(ATLL);
- •Patients with active central nervous system (CNS) infiltration, including invasion of brain parenchyma, meninges or compression of spinal cord;
- •Diagnosed as cutaneous extranodal nasal type T-cell lymphoma;
- •Immunohistochemistry confirmed PD-1 positive;
- •Patients with complicated diseases, including autoimmune disease, type I diabetes, hypothyroidism requiring hormone replacement (except Hashimoto's thyroiditis) and severe mental disease;
- •The patients received systemic corticosteroids (prednisone > 10 mg/day or equivalent dose) within 2 weeks before the first administration or patients who need systemic corticosteroids therapy during the study;
- •The patients received radiotherapy, chemotherapy, hormone therapy, surgery, targeted therapy or systemic treatment of antibody drugs within 4 weeks before the first administration; the patients used monoclonal antibody coupled radionuclide or cytotoxin therapy within 10 weeks before the first administration; the toxicity of the previous anti-tumor treatment did not recover to ≤ level 1 (except hair loss);
- •Uncontrolled hypertension (systolic blood pressure > 180mmHg and/or diastolic blood pressure > 100mmHg);
- •Previous history of organ transplantation or allogeneic hematopoietic stem cell transplantation;
- •The patients who had autologous hematopoietic stem cell transplantation within 3 months before the first administration;
- •Patients receiving any attenuated vaccine within 4 weeks before the first administration or during the study;
- •Patients who are allergic to macromolecular protein or anti-PD-1 antibody;
- •Patients who with previous or concurrent malignancies (except skin basal cell carcinoma and cervical carcinoma in situ, which have been cured for more than 3 years);
- •Had uncontrollable or serious cardiovascular diseases, the heart of New YorkNYHA standard grade 3-4 history of chronic heart failure, unstable angina, myocardial infarction and other cardiovascular diseases within 6 months before the first administration;
- •HIV positive patients, or active hepatitis (hepatitis B: hepatitis B five items and HBV-DNA, transaminase, etc., hepatitis C: HCV antibody and HCV RNA);
- •Patients who had been previously treated with any other investigational drugs/devices within 4 weeks before the first administration;
- •Patients with drug abuse history or alcohol addiction history within 6 months before the first administration;
- •Patients who were previously treated with anti PD-1 antibody, anti PD-L1 antibody, anti PD-L2 antibody, anti-137 or anti CTLA-4 antibody (or any other antibodies acting on T cell co-stimulation or checkpoint pathway);
- •Patients with current or previous interstitial lung diseases (except for interstitial lung disease caused by radiotherapy and chemotherapy and currently without symptoms);
- •Active infections requiring systemic treatment;
- •Patients with active pulmonary tuberculosis;
- •pregnant or lactating women, female patients with pregnancy plan or male patients with such plan from the study period to 6 months after the last medication, who are unwilling to use an effective contraceptive measure (such as IUD or condom) approved by medicine during the trial period;
- •Subjects who are considered unsuitable for participating in this study for various reasons at the discretion of the investigator.
研究组 & 干预措施
Single arm
Experimental
干预措施: F520 (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: Approximately 24 months
To evaluate the efficacy of F520 as defined by objective response rate (evaluated by IRC) in patients with relapsed or refractory PTCL.
次要结局
- Progression-free survival (PFS)(Approximately 24 months)
- Time to response (TTR)(Approximately 24 months)
- Duration of response (DOR)(Approximately 24 months)
- Overall survival (OS)(Approximately 24 months)
- Completed response rate (CRR)(Approximately 24 months)
- Disease control rate (DCR)(Approximately 24 months)
- Objective response rate (ORR)(Approximately 24 months)
研究者
相似试验
Unknown
2 期
A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)Secondary Central Nervous System LymphomaPrimary Central Nervous System LymphomaNCT04457869Shandong New Time Pharmaceutical Co., LTD43
已完成
2 期
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMEDBreast CancerNCT05520723MedSIR50
进行中（未招募）
不适用
A phase 2, multicenter, open-label, single arm, two-stage study to evaluate the efficacy and safety of CC-4047 (Pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to systemic anticancer therapyEUCTR2007-005670-31-ATCelgene Corporation167
招募中
1 期
A study to evaluate safety and efficacy of SOT101 in combination with pembrolizumab in patients with selected advanced/refractory solid tumorsEUCTR2021-005774-25-BESOTIO Biotech AG320
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of SOT101 in combination with cetuximab in patients with a specific subtype of colon and/or rectum cancerRAS wild-type colorectal cancerEUCTR2022-001527-32-BESOTIO Biotech AG52